Page 41 - TheLeekCovidEdition_1
P. 41
Mr. Trump’s customary impulse would be to select the stock winner CytoDyn. On the other hand, the company is based in Vancouver, Socialist Canada, which would likely put the president crosswise with a large segment of his base. Roche (Swiss) and Takeda (Japan) are also foreign-based.
Prior to Shinzo Abe’s retirement, Trump’s bromance with the prime minister would have made Takeda a shoo-in. However, Mr. Abe’s successor, Yoshihide Suga, was born to a family of strawberry farmers and worked at a cardboard factory to pay his college tuition, making PM Suga an unlikely suck-up.
Political oddsmakers favor CytoDyn because Mr. Trump is obsessed with winning and winners, but this is a brand new show, so “anything can happen,” as the president likes to say.
The formal name of Mr. Trump’s Covid-45 contest is expected by the end of the day. Stay tuned.
This story will be updated as new pandemic treatment winners are announced.
